Article successfully added.

CyFlow™ HLA-DR PerCP-Cy5.5

CyFlow™ HLA-DR PerCP-Cy5.5
Antibody: Yes
Antigen: HLA-DR
Application: Flow cytometry
Clonality: monoclonal
Clone: L243
Emission Maximum: 695 nm
Excitation Maximum: 482 nm
Field of Interest: MHC
Format/Fluorochrome: PerCP-Cy5.5
Isotype: IgG2a
Laser: Blue , Green
Regulatory Status: RUO
Source Species: Mouse
Target Species: Dog, Human, Non-Human Primates
Product number: AU107604

For Research Use Only

$340.00 USD*

Price excludes any applicable taxes plus shipping costs

Description Documentation TDS & SDS
Description
Quantity 100 tests Volume 0.4 mL Immunogen Human B lymphocytes Background... more
Close menu
CyFlow™ HLA-DR PerCP-Cy5.5
Quantity100 tests
Volume0.4 mL
ImmunogenHuman B lymphocytes
Background InformationHLA-DR is a member of MHC class II glycoproteins which bind intracellularly processed peptides and present them to the Th cells. HLA-DR is composed of 36 kDa α chain and 27 kDa β chain, both anchored in the plasma membrane. Together with other MHC II molecules HLA-DR plays a central role in the immune system.
UsageThe reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 4·µl reagent·/ 100·µl of whole blood or 10^6 cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.
Storage BufferThe reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.
Specific References

| Coral S, Pucillo C, Leonardi A, Fonsatti E, Altomonte M, Maio M: Triggering of HLA‑DR antigens differentially modulates tumor necrosis factor alpha release by B cells at distinct stage of maturation. Cell Growth Differ. 1997 May; 8(5):581‑8. < PMID: 9149909 > | Cantin R, Martin G, Tremblay MJ: A novel virus capture assay reveals a differential acquisition of host HLA‑DR by clinical isolates of human immunodeficiency virus type 1 expanded in primary human cells depending on the nature of producing cells and the donor source. J Gen Virol. 2001 Dec; 82(12):2979‑87. < PMID: 11714974 > | Kalka-Moll WM, Tzianabos AO, Bryant PW, Niemeyer M, Ploegh HL, Kasper DL: Zwitterionic polysaccharides stimulate T cells by MHC class II‑dependent interactions. J Immunol. 2002 Dec 1; 169(11):6149‑53. < PMID: 12444118 > | Bouillon M, El Fakhry Y, Girouard J, Khalil H, Thibodeau J, Mourad W: Lipid raft‑dependent and ‑independent signaling through HLA‑DR molecules. J Biol Chem. 2003 Feb 28; 278(9):7099‑107. < PMID: 12499388 > | Muczynski KA, Ekle DM, Coder DM, Anderson SK: Normal human kidney HLA‑DR‑expressing renal microvascular endothelial cells: characterization, isolation, and regulation of MHC class II expression. J Am Soc Nephrol. 2003 May; 14(5):1336‑48. < PMID: 12707403 > | De Gassart A, Camosseto V, Thibodeau J, Ceppi M, Catalan N, Pierre P, Gatti E: MHC class II stabilization at the surface of human dendritic cells is the result of maturation‑dependent MARCH I down‑regulation. Proc Natl Acad Sci USA. 2008 Mar 4; 105(9):3491‑6. < PMID: 18305173 > | Swiatek-de Lange M, Rist W, Stahl HF, Weith A, Lenter MC: Comment on "MHC class II expression identifies functionally distinct human regulatory T cells". J Immunol. 2008 Mar 15; 180(6):3625. < PMID: 18322165 > | Ivanov A, Beers SA, Walshe CA, Honeychurch J, Alduaij W, Cox KL, Potter KN, Murray S, Chan CH, Klymenko T, Erenpreisa J, Glennie MJ, Illidge TM, Cragg MS: Monoclonal antibodies directed to CD20 and HLA‑DR can elicit homotypic adhesion followed by lysosome‑mediated cell death in human lymphoma and leukemia cells. J Clin Invest. 2009 Aug; 119(8):2143‑59. < PMID: 19620786 >

TDS & SDS
Close menu

Technical Data Sheet

Safety Data Sheet